FMA
RIGL icon

FNY Managed Accounts’s Rigel Pharmaceuticals RIGL Stock Holding History

FNY Managed Accounts’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$2K Buy
+72
New +$2.88K ﹤0.01% 420
2016
Q4 		– Sell
-2,000
Closed -$73.4K – 228
2016
Q3 		$73.4K Buy
+2,000
New +$57.3K 0.06% 174

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FNY Managed Accounts's RIGL Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in Rigel Pharmaceuticals (RIGL) in Q1 2018: 72 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #420 among its holdings. This is a return to the name: FNY Managed Accounts previously reported a position in RIGL as recently as Q3 2016.

FNY Managed Accounts first reported a position in RIGL in Q3 2016 and has held it in 2 quarters since. The position peaked at $73.4K in Q3 2016. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2018.

  • FNY Managed Accounts held 72 shares of Rigel Pharmaceuticals worth $2K as of Q1 2018.
  • Rigel Pharmaceuticals was a new FNY Managed Accounts position in Q1 2018.
  • Rigel Pharmaceuticals made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #420 holding.
  • FNY Managed Accounts first reported a position in Rigel Pharmaceuticals in Q3 2016 and has held it in 2 quarters since.
  • FNY Managed Accounts's Rigel Pharmaceuticals position peaked at $73.4K in Q3 2016.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.